Seikagaku Corporation   Report issue

For profit Phase 2 Phase 3
Founded: Tokyo Japan (1947)

Organization Overview

First Clinical Trial
2007
NCT01282606
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Seikagaku Corporation

Active Ingredients

Drugs in Phase 3 Trials (2)

condoliase (Hernicore) (5 trials)

si-614 (3 trials)

Drugs in Phase 2 Trials (1)

si-722 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cystitis (Phase 2)

Cystitis, Interstitial (Phase 2)

Dry Eye Syndromes (Phase 3)

Hernia (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Spinal Diseases (Phase 3)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 3